Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

NCT06607757 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

Interventions

DRUG: Capivasertib
DRUG: Fulvestrant injection

Sponsor

GBG Forschungs GmbH

Collaborators

[object Object]